Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...

For Washington residents, please visit our Washington Health Data Privacy Policy to review our privacy practices related to your health data.

Pfizer believes that privacy is a fundamental right. Personal data is at the core of scientific and medical innovation, and your personal health data can play a critical role in helping you and your ...

At Pfizer, we’re relentless in our pursuit of breakthroughs that change patients’ lives. But delivering medicines and vaccines worldwide is not a simple undertaking. Pfizer Global Supply — or PGS — ...

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...

Initial agreement provides up to 40 million doses to COVAX in 2021 First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility ...

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic ...

“2025 was a year of strong execution and strategic progress for Pfizer. We’ve strengthened our foundation, advanced our R&D pipeline and positioned our company for sustainable growth in the post-LOE ...